- Home
- LADR vs PRAX Comparison
LADR vs PRAX Comparison
Compare LADR & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LADR
- PRAX
- Stock Information
- Founded
- LADR 2008
- PRAX 2015
- Country
- LADR United States
- PRAX United States
- Employees
- LADR N/A
- PRAX N/A
- Industry
- LADR Real Estate Investment Trusts
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- LADR Real Estate
- PRAX Health Care
- Exchange
- LADR Nasdaq
- PRAX Nasdaq
- Market Cap
- LADR 1.5B
- PRAX 1.4B
- IPO Year
- LADR 2014
- PRAX 2020
- Fundamental
- Price
- LADR $11.26
- PRAX $83.68
- Analyst Decision
- LADR Buy
- PRAX Strong Buy
- Analyst Count
- LADR 6
- PRAX 9
- Target Price
- LADR $13.29
- PRAX $149.11
- AVG Volume (30 Days)
- LADR 581.3K
- PRAX 350.3K
- Earning Date
- LADR 02-06-2025
- PRAX 03-04-2025
- Dividend Yield
- LADR 8.22%
- PRAX N/A
- EPS Growth
- LADR N/A
- PRAX N/A
- EPS
- LADR 0.76
- PRAX N/A
- Revenue
- LADR $257,005,000.00
- PRAX $1,605,000.00
- Revenue This Year
- LADR N/A
- PRAX N/A
- Revenue Next Year
- LADR N/A
- PRAX N/A
- P/E Ratio
- LADR $14.56
- PRAX N/A
- Revenue Growth
- LADR N/A
- PRAX N/A
- 52 Week Low
- LADR $10.10
- PRAX $33.01
- 52 Week High
- LADR $12.48
- PRAX $86.93
- Technical
- Relative Strength Index (RSI)
- LADR 52.12
- PRAX 62.96
- Support Level
- LADR $11.00
- PRAX $73.50
- Resistance Level
- LADR $11.33
- PRAX $83.24
- Average True Range (ATR)
- LADR 0.18
- PRAX 4.30
- MACD
- LADR 0.03
- PRAX 0.89
- Stochastic Oscillator
- LADR 83.72
- PRAX 94.95
About LADR Ladder Capital Corp
Ladder Capital Corp is an internally-managed real estate investment trust that is in commercial real estate finance. The company originates and invests in a diverse portfolio of commercial real estate and real estate-related assets, focusing on senior secured assets. The company's investment activities include: (i) Primary business of originating senior first mortgage fixed and floating rate loans collateralized by commercial real estate with flexible loan structures; (ii) owning and operating commercial real estate, including net leased commercial properties; and (iii) investing in investment-grade securities secured by first mortgage loans on commercial real estate. The company has three reportable segments include loans: which derives maximum profit; securities; and real estate.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.